Expressions of CCR3 and CCL5 in serum of patients with non-small cell lung cancer and their predictive value for recurrence and metastasis after surgery
10.3760/cma.j.cn115355-20230602-00287
- VernacularTitle:非小细胞肺癌患者血清CCR3和CCL5表达及其对术后复发转移的预测价值
- Author:
Shilin DING
1
;
Xiaohong MA
Author Information
1. 如皋市人民医院检验科，南通 226500
- Keywords:
Carcinoma, non-small cell lung;
CC chemokine receptor 3;
Chemokine CCL5;
Recurrence;
Neoplasm metastasis
- From:
Cancer Research and Clinic
2023;35(9):670-674
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expressions of CC chemokine receptor 3 (CCR3) and CC chemokine 5 (CCL5) in serum of patients with non-small cell lung cancer (NSCLC) and their predictive value for recurrence and metastasis after surgery.Methods:The clinical data of 90 NSCLC patients (NSCLC group) who underwent surgery in Rugao People's Hospital from January 2017 to December 2020 were retrospectively analyzed. At the same time, 95 healthy people who underwent physical examination during the same period were selected as the healthy control group. The levels of serum CCR3 and CCL5 in the two groups were detected by enzyme-linked immunosorbent assay. After a 2-year postoperative follow-up, the NSCLC patients were recorded for recurrence and metastasis after surgery. Multivariate logistic regression analysis was used to identify the independent factors affecting patients' recurrence and metastasis after surgery. Receiver operating characteristic (ROC) curve was used to evaluate the predictive efficacy of CCR3 and CCL5 levels for patients' recurrence and metastasis after surgery.Results:The levels of CCR3 and CCL5 in NSCLC group were higher than those in the healthy control group [(290±36) pg/ml vs. (183±23) pg/ml; (15.7±3.1) pg/ml vs. (6.2±1.2) pg/ml], and the differences were statistically significant ( t values were 24.02 and 27.24, both P < 0.001). The incidence of recurrence and metastasis after surgery in NSCLC group was 34.44% (31/90). The levels of CCR3 and CCL5 in patients with recurrence and metastasis were higher than those in patients without recurrence and metastasis [(315±39) pg/ml vs. (276±35) pg/ml; (17.5±3.4) pg/ml vs. (14.7±2.9) pg/ml], and the differences were statistically significant ( t values were 4.87 and 4.04, both P < 0.001). The result of univariate analysis showed that the proportions of patients with stage Ⅲ A, poorly differentiation and lymph node metastasis in patients with recurrence and metastasis were higher than those in patients without recurrence and metastasis (all P < 0.05). Multivariate logistic regression analysis showed that TNM stage ( OR = 2.587, 95% CI 1.509-4.434), CCR3 level ( OR = 2.215, 95% CI 1.354-3.623) and CCL5 level ( OR = 2.343, 95% CI 1.193-4.598) were independent factors affecting patients' recurrence and metastasis after surgery (all P < 0.05). ROC curve analysis showed that the areas under the curve (AUC) of CCR3, CCL5 and combination of the two in predicting NSCLC patients' recurrence and metastasis after surgery were 0.710, 0.684 and 0.854. Conclusions:The abnormal high expressions of CCR3 and CCL5 in the serum of NSCLC patients are independent risk factors for recurrence and metastasis after surgery. The combined detection of CCR3 and CCL5 can effectively predict the recurrence and metastasis of patients after surgery.
